For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

Aggregated insoluble tau is one of two defining features of Alzheimer's disease. Because
clinical symptoms are strongly correlated with tau aggregates, drug development and …

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Abstract α-Synuclein aggregates constitute the pathology of Lewy body (LB) disease. Little is
known about the effects of LB pathology in preclinical (presymptomatic) individuals, either as …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Background Tauopathies are a class of neurodegenerative disorders characterized by
neuronal and/or glial tau-positive inclusions. Main body Clinically, tauopathies can present …

Background Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau
phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau …